August 11, 2022

Oncopeptides publishes Q2 report 2022

STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hemato...
Read more
August 11, 2022

Targovax ASA: Invitation to Targovax’s second quarter and first half 2022 presentation, Thursday 18 August

Oslo, Norway, 11 August 2022 – Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2022 results on Thursday 18 August 2022. Targovax’s management will pre...
Read more
August 10, 2022

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease

PHILADELPHIA, PA., AUGUST 10, 2022 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. ...
Read more
August 10, 2022

Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Busines...
Read more
August 9, 2022

Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results And Clinical Program Updates

FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administ...
Read more
August 3, 2022

Pulmonx Reports Second Quarter 2022 Financial Results

Aug 2, 2022PDF Version REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally...
Read more
July 27, 2022

InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation

Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pic...
Read more
July 26, 2022

Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225

Brussels, Belgium and Berlin, Germany, 26 July 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, and Eckert &...
Read more
July 20, 2022

FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto

STOCKHOLM — July 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematolo...
Read more
July 15, 2022

BONESUPPORT HOLDING AB (PUBL) – PUBLISHES Q2 2022 INTERIM REPORT

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2022.STRONG SALES...
Read more